MA27478A1 - Ligands des recepteurs de la melanocortine - Google Patents
Ligands des recepteurs de la melanocortineInfo
- Publication number
- MA27478A1 MA27478A1 MA28235A MA28235A MA27478A1 MA 27478 A1 MA27478 A1 MA 27478A1 MA 28235 A MA28235 A MA 28235A MA 28235 A MA28235 A MA 28235A MA 27478 A1 MA27478 A1 MA 27478A1
- Authority
- MA
- Morocco
- Prior art keywords
- butyl
- alkyl
- benzyl
- methylallyl
- fluorophenyl
- Prior art date
Links
- 239000003446 ligand Substances 0.000 title 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 3
- -1 clohexylmethyl Chemical group 0.000 abstract 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 abstract 1
- 125000006710 (C2-C12) alkenyl group Chemical group 0.000 abstract 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 abstract 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 abstract 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 abstract 1
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 abstract 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 abstract 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 abstract 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
- 125000005394 methallyl group Chemical group 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
- C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Gynecology & Obstetrics (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Pregnancy & Childbirth (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Child & Adolescent Psychology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
Abstract
La présente invention se rapporte à des composés qui possèdent un squelette sous forme de cycle contenant de l'azote, substitué par une unité alkyle R1 sélectionnée parmi alkyle C1-C12 linéaire ou ramifié, alkyle C3-C8 cyclique, alcényle C2-C12 linéaire ou ramifié, ou haloalkyle, c'est-à-dire, par exemple, aux 2-kéto-3-alkylpipérazines représentées par la formule (I). Dans ladite formule : R est sélectionné parmi phényle, 3-fluorophényle, 4-fluorophényle, 3,5-difluorophényle, et 4-chlorophényle ; R1 est sélectionné parmi méthyle, éthyle, propyle, iso-propyle, butyle, iso-butyle, sec-butyle, tert-butyle, cyclopropyle, cyclopropylméthyle, cyclopentyle, cyclopentylméthyle, cyclohexyle, clohexylméthyle, benzyle, allyle, 1-méthylallyle, 2-méthylallyle, but-2-ényle, et propargyle ; R7a est sélectionné parmi hydrogène, -CO2H, -CONH2, -CONHCH3, and -CON(CH3)2; R8 représente benzyle, benzyle substitué, ou naphthalén-2-ylméthyle.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42057802P | 2002-10-23 | 2002-10-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA27478A1 true MA27478A1 (fr) | 2005-08-01 |
Family
ID=32176593
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA28235A MA27478A1 (fr) | 2002-10-23 | 2005-04-25 | Ligands des recepteurs de la melanocortine |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US7132539B2 (fr) |
| EP (1) | EP1556361A2 (fr) |
| JP (1) | JP2006506384A (fr) |
| KR (1) | KR20050072445A (fr) |
| CN (1) | CN1703221A (fr) |
| AR (1) | AR043054A1 (fr) |
| AU (1) | AU2003286557A1 (fr) |
| BR (1) | BR0315614A (fr) |
| CA (1) | CA2501231A1 (fr) |
| MA (1) | MA27478A1 (fr) |
| MX (1) | MXPA05004378A (fr) |
| NO (1) | NO20052476L (fr) |
| PE (1) | PE20040778A1 (fr) |
| PL (1) | PL376702A1 (fr) |
| RU (1) | RU2005111967A (fr) |
| TW (1) | TW200504033A (fr) |
| WO (1) | WO2004037797A2 (fr) |
| ZA (1) | ZA200502944B (fr) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2574156A1 (fr) | 2004-07-19 | 2006-02-23 | Merck & Co., Inc. | Derives de piperidine acyles utilises en tant qu'agonistes du recepteur de la melanocortine 4 |
| CA2666193A1 (fr) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Imidazolidin-2,4-dione arylaminoaryl-alkyl-substituee, son procede de fabrication, medicament contenant ce compose et son utilisation |
| US8163779B2 (en) | 2006-12-20 | 2012-04-24 | Takeda San Diego, Inc. | Glucokinase activators |
| US8173645B2 (en) * | 2007-03-21 | 2012-05-08 | Takeda San Diego, Inc. | Glucokinase activators |
| EP2025674A1 (fr) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament |
| KR101478253B1 (ko) * | 2007-09-17 | 2014-12-31 | 국민대학교산학협력단 | 아룸 팔래스티눔(Ａｒｕｍ ｐａｌａｅｓｔｉｎｕｎＢｏｉｓｓ) 유래 항암용 피페라지움 화합물 |
| UY31968A (es) | 2008-07-09 | 2010-01-29 | Sanofi Aventis | Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos |
| AU2009314200B2 (en) | 2008-11-17 | 2011-11-17 | Merck Sharp & Dohme Corp. | Substituted bicyclic amines for the treatment of diabetes |
| WO2010068601A1 (fr) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant |
| WO2011011506A1 (fr) | 2009-07-23 | 2011-01-27 | Schering Corporation | Composés oxazépine spirocyclique en tant qu'inhibiteurs de la stéaroyl-coenzyme a delta-9 désaturase |
| WO2011011508A1 (fr) | 2009-07-23 | 2011-01-27 | Schering Corporation | Composés doxazépine benzofusionnés en tant quinhibiteurs de la coenzyme-stéaroyle a delta-9 désaturase |
| UY32826A (es) | 2009-08-04 | 2011-02-28 | Takeda Pharmaceutical | Compuestos heterocíclicos |
| AU2010288523A1 (en) | 2009-08-26 | 2012-03-15 | Sanofi | Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use |
| WO2011137024A1 (fr) | 2010-04-26 | 2011-11-03 | Merck Sharp & Dohme Corp. | Nouveaux inhibiteurs de spiropipéridine prolylcarboxypeptidase |
| US9365539B2 (en) | 2010-05-11 | 2016-06-14 | Merck Sharp & Dohme Corp. | Prolylcarboxypeptidase inhibitors |
| WO2011156246A1 (fr) | 2010-06-11 | 2011-12-15 | Merck Sharp & Dohme Corp. | Nouveaux inhibiteurs de prolylcarboxypeptidase |
| US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| US8846666B2 (en) | 2011-03-08 | 2014-09-30 | Sanofi | Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
| EP2683699B1 (fr) | 2011-03-08 | 2015-06-24 | Sanofi | Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation |
| US8809324B2 (en) | 2011-03-08 | 2014-08-19 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
| WO2012120053A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés oxathiazine ramifiés, procédé pour leur préparation, utilisation en tant que médicament, agents pharmaceutiques contenant ces dérivés et leur utilisation |
| US8901114B2 (en) | 2011-03-08 | 2014-12-02 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
| US8809325B2 (en) | 2011-03-08 | 2014-08-19 | Sanofi | Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof |
| EP2683700B1 (fr) | 2011-03-08 | 2015-02-18 | Sanofi | Dérivés d'oxathiazine tétra-substitués, leur procédé de fabrication, leur utilisation comme médicament ainsi que médicaments en étant pourvu et leur utilisation |
| WO2012120057A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Nouveaux dérivés phényl-oxathiazine substitués, procédé pour leur préparation, agent pharmaceutique contenant ces composés et leur utilisation |
| US9321749B1 (en) | 2012-07-25 | 2016-04-26 | Globavir Biosciences, Inc. | Heterocyclic compounds and uses thereof |
| RU2731913C2 (ru) * | 2015-08-04 | 2020-09-09 | Астеллас Фарма Инк. | Пиперазиновое производное |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4251438A (en) | 1979-06-14 | 1981-02-17 | The Upjohn Company | Piperazinone and piperazine polypeptides |
| US5578593A (en) | 1992-12-11 | 1996-11-26 | Merck & Co., Inc. | Spiro piperidines and homologs promote release of growth hormone |
| SK282166B6 (sk) | 1992-12-11 | 2001-11-06 | Merck & Co., Inc. | Spiropiperidínové deriváty, spôsob ich výroby a farmaceutický prostriedok s ich obsahom |
| US5556853A (en) * | 1993-10-29 | 1996-09-17 | Takeda Chemical Industries, Ltd. | Epoxysuccinic acid derivatives |
| US5492916A (en) | 1993-12-23 | 1996-02-20 | Merck & Co., Inc. | Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone |
| US5494919A (en) | 1993-11-09 | 1996-02-27 | Merck & Co., Inc. | 2-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone |
| US5721251A (en) | 1993-12-10 | 1998-02-24 | Merck & Co., Inc. | Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone |
| US5721250A (en) | 1993-12-23 | 1998-02-24 | Merck & Co. Inc. | Di-and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone |
| AU3128195A (en) | 1994-07-20 | 1996-02-16 | Merck & Co., Inc. | Piperidines and hexahydro-1h-azepines spiro substituted at the 4-position promote release of growth hormone |
| US5767118A (en) | 1994-10-26 | 1998-06-16 | Merck & Co., Inc. | 4-Heterocyclic peperidines promote release of growth hormone |
| US5889006A (en) | 1995-02-23 | 1999-03-30 | Schering Corporation | Muscarinic antagonists |
| IL117798A (en) | 1995-04-07 | 2001-11-25 | Schering Plough Corp | Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them |
| WO1996038471A1 (fr) | 1995-05-29 | 1996-12-05 | Pfizer Inc. | Dipeptides favorisant la secretion de l'hormone de croissance |
| GB9612276D0 (en) | 1996-06-12 | 1996-08-14 | Merck & Co Inc | 4-Spiroindoline piperidines promote release of growth hormone |
| US5804578A (en) | 1996-04-03 | 1998-09-08 | Merck & Co., Inc. | Piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone |
| AU4342097A (en) | 1996-09-13 | 1998-04-02 | Merck & Co., Inc. | Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone |
| US5877182A (en) | 1996-09-13 | 1999-03-02 | Merck & Co., Inc. | Piperidines promote release of growth hormone |
| US5965565A (en) | 1996-12-12 | 1999-10-12 | Merck & Co., Inc. | Piperidines promote release of growth hormone |
| GB9709972D0 (en) | 1997-05-19 | 1997-07-09 | Pfizer Ltd | Tetrazoles |
| US6127381A (en) | 1998-04-28 | 2000-10-03 | Basu; Amaresh | Isoquinoline compound melanocortin receptor ligands and methods of using same |
| PL194560B1 (pl) | 1998-05-11 | 2007-06-29 | Novo Nordisk As | Związki o właściwościach uwalniania hormonu wzrostu, kompozycja farmaceutyczna zawierająca te związki oraz ich zastosowanie |
| CA2334551A1 (fr) | 1998-06-11 | 1999-12-16 | Merck & Co., Inc. | Derives de spiropiperidine en tant qu'agonistes des recepteurs de la melanocortine |
| US6294534B1 (en) | 1998-06-11 | 2001-09-25 | Merck & Co., Inc. | Spiropiperidine derivatives as melanocortin receptor agonists |
| JP3390744B2 (ja) | 1998-09-22 | 2003-03-31 | 山之内製薬株式会社 | シアノフェニル誘導体 |
| DK1175401T3 (da) | 1999-05-04 | 2005-11-14 | Schering Corp | Piperazinderivater, der er nyttige som CCR5-antagonister |
| AU766191B2 (en) | 1999-06-04 | 2003-10-09 | Merck & Co., Inc. | Substituted piperidines as melanocortin-4 receptor agonists |
| WO2001005331A1 (fr) | 1999-07-16 | 2001-01-25 | Biocompatibles Ltd | Endoprothese tressee |
| AU4928101A (en) | 2000-03-23 | 2001-10-03 | Merck & Co Inc | Spiropiperidine derivatives as melanocortin receptor agonists |
| JP2003528088A (ja) | 2000-03-23 | 2003-09-24 | メルク エンド カムパニー インコーポレーテッド | メラノコルチン受容体作働薬としての置換ピペリジン類 |
| AU2001264977B2 (en) | 2000-05-30 | 2005-04-14 | Merck & Co., Inc. | Melanocortin receptor agonists |
| CN1440406A (zh) | 2000-06-28 | 2003-09-03 | 辉瑞产品公司 | 黑皮质素受体配体 |
| WO2002015909A1 (fr) | 2000-08-23 | 2002-02-28 | Merck & Co., Inc. | Piperidines substituees en tant qu'agonistes de recepteurs de la melanocortine |
| US6573264B1 (en) | 2000-10-23 | 2003-06-03 | Cv Therapeutics, Inc. | Heteroaryl alkyl piperazine derivatives |
| GB0030710D0 (en) | 2000-12-15 | 2001-01-31 | Hoffmann La Roche | Piperazine derivatives |
| EP1358163A1 (fr) | 2001-01-23 | 2003-11-05 | Eli Lilly And Company | Agonistes de recepteurs de melanocortine |
| JP2004523529A (ja) | 2001-01-23 | 2004-08-05 | イーライ・リリー・アンド・カンパニー | メラノコルチンレセプターアゴニスト |
| JP2004521117A (ja) | 2001-01-23 | 2004-07-15 | イーライ・リリー・アンド・カンパニー | メラノコルチン受容体アゴニストとしての置換ピペリジン／ピペラジン |
| ES2272703T3 (es) | 2001-02-28 | 2007-05-01 | MERCK & CO., INC. | Derivados de piperidina acilados como agonistas de receptor de melanocortina-4. |
| CA2439152C (fr) | 2001-02-28 | 2008-06-17 | Merck & Co., Inc. | Derives de piperidine acylee tels que les agonistes du recepteur 4 de la melanocortine |
| JP2004532838A (ja) | 2001-03-02 | 2004-10-28 | ブリストル−マイヤーズ スクイブ カンパニー | メラノコルチン受容体のモデュレーターとして有用な化合物及びそれを含む製薬組成物 |
| US6900329B2 (en) | 2001-03-21 | 2005-05-31 | Schering Corporation | MCH antagonists and their use in the treatment of obesity |
| ES2342942T3 (es) | 2001-03-29 | 2010-07-19 | Schering Corporation | Antagonistas de ccr5 utiles para el tratamiento del sida. |
| US6911447B2 (en) | 2001-04-25 | 2005-06-28 | The Procter & Gamble Company | Melanocortin receptor ligands |
| US7115607B2 (en) * | 2001-07-25 | 2006-10-03 | Amgen Inc. | Substituted piperazinyl amides and methods of use |
| WO2003013571A1 (fr) | 2001-08-10 | 2003-02-20 | Palatin Technologies, Inc. | Peptidomimetiques de metallopeptides biologiquement actifs |
| US7354923B2 (en) * | 2001-08-10 | 2008-04-08 | Palatin Technologies, Inc. | Piperazine melanocortin-specific compounds |
| MY141661A (en) | 2001-09-06 | 2010-05-31 | Schering Corp | 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
| WO2003031410A1 (fr) | 2001-10-09 | 2003-04-17 | Neurocrine Biosciences, Inc. | Ligands de recepteurs de la melanocortine et compositions et methodes associees |
| CZ2004519A3 (cs) | 2001-10-22 | 2004-12-15 | Pfizer Products Inc. | Deriváty piperazinu s účinky antagonisty receptoru CCR1 |
| CA2473036A1 (fr) | 2002-01-23 | 2003-07-31 | Paul Leslie Ornstein | Agonistes du recepteur de la melanocortine |
-
2003
- 2003-10-20 TW TW092129035A patent/TW200504033A/zh unknown
- 2003-10-20 US US10/689,022 patent/US7132539B2/en not_active Expired - Fee Related
- 2003-10-22 RU RU2005111967/04A patent/RU2005111967A/ru not_active Application Discontinuation
- 2003-10-22 PL PL376702A patent/PL376702A1/pl not_active Application Discontinuation
- 2003-10-22 WO PCT/US2003/033402 patent/WO2004037797A2/fr active Application Filing
- 2003-10-22 AR ARP030103859A patent/AR043054A1/es not_active Application Discontinuation
- 2003-10-22 AU AU2003286557A patent/AU2003286557A1/en not_active Abandoned
- 2003-10-22 EP EP03777759A patent/EP1556361A2/fr not_active Withdrawn
- 2003-10-22 MX MXPA05004378A patent/MXPA05004378A/es unknown
- 2003-10-22 PE PE2003001070A patent/PE20040778A1/es not_active Application Discontinuation
- 2003-10-22 CN CNA2003801009342A patent/CN1703221A/zh active Pending
- 2003-10-22 BR BR0315614-1A patent/BR0315614A/pt not_active IP Right Cessation
- 2003-10-22 CA CA002501231A patent/CA2501231A1/fr not_active Abandoned
- 2003-10-22 JP JP2004546990A patent/JP2006506384A/ja active Pending
- 2003-10-22 KR KR1020057006836A patent/KR20050072445A/ko not_active Ceased
-
2005
- 2005-04-12 ZA ZA200502944A patent/ZA200502944B/en unknown
- 2005-04-25 MA MA28235A patent/MA27478A1/fr unknown
- 2005-05-23 NO NO20052476A patent/NO20052476L/no not_active Application Discontinuation
-
2006
- 2006-06-23 US US11/473,972 patent/US20060247224A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2005111967A (ru) | 2006-01-20 |
| TW200504033A (en) | 2005-02-01 |
| KR20050072445A (ko) | 2005-07-11 |
| AU2003286557A1 (en) | 2004-05-13 |
| US7132539B2 (en) | 2006-11-07 |
| CA2501231A1 (fr) | 2004-05-06 |
| EP1556361A2 (fr) | 2005-07-27 |
| AR043054A1 (es) | 2005-07-13 |
| BR0315614A (pt) | 2005-08-30 |
| JP2006506384A (ja) | 2006-02-23 |
| US20060247224A1 (en) | 2006-11-02 |
| CN1703221A (zh) | 2005-11-30 |
| NO20052476D0 (no) | 2005-05-23 |
| PL376702A1 (pl) | 2006-01-09 |
| ZA200502944B (en) | 2006-02-22 |
| WO2004037797A2 (fr) | 2004-05-06 |
| US20050010031A1 (en) | 2005-01-13 |
| NO20052476L (no) | 2005-05-23 |
| PE20040778A1 (es) | 2004-12-21 |
| MXPA05004378A (es) | 2005-07-05 |
| WO2004037797A3 (fr) | 2004-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA27478A1 (fr) | Ligands des recepteurs de la melanocortine | |
| MA26879A1 (fr) | Compositions pharmaceutiques contenant des derives de 3-amino-azetidine, les nouveaux derives et leur preparation. | |
| MA33832B1 (fr) | Isoquinolinones et quinazolinones substituées | |
| MA27573A1 (fr) | Sinomenine et derives de sinomenine, synthese et utilisation. | |
| MA29250B1 (fr) | Cyclohexylamides servant d'antagonistes des recepteurs de dopamine d3, d2 et de 5ht1a | |
| MA28024A1 (fr) | Derives de (thio) carbamoyl-cyclohexane utilises en tant qu'antagonistes des recepteurs d3/d2 | |
| DK0915866T3 (da) | Forbedret fremgangsmåde til syntese af beskyttende estere af (S)-3,4-dihydroxysmørsyre | |
| RU2332212C2 (ru) | Аминоспирт | |
| PE20040164A1 (es) | Mimeticos de glucocorticoides, procedimientos para su preparacion y composiciones farmaceuticas | |
| TNSN07178A1 (fr) | N-sulfonylaminobenzyl-2-phenoxy-acetamides substitues | |
| MA30428B1 (fr) | Derives de dihydropyrazolopyrimidinones | |
| MA28271A1 (fr) | Dérivés de benzènesulfonylamino-pyridine -2-yle et composés apparentés servant d'inhibiteurs de la 11-bêta- hydroxystéroïde-déshydrogénase de type 1(11-bêta-HSD-1)pour le traitement du diabète et de l'obésité | |
| MA27582A1 (fr) | Derives benzazepine pour le traitement de troubles neurologiques | |
| PA8610801A1 (es) | Compuestos de aril o heteroaril amida | |
| MA29649B1 (fr) | Nouveaux derives de 2,4- dianilinopyrimidines, leur preparation, a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk | |
| CA2394086A1 (fr) | Derives de 4-aminopiperidine et leur utilisation en tant que medicament | |
| TNSN05073A1 (fr) | Quinazolinones spirocondensees nouvelles et leur utilisation comme inhibiteurs de phosphodiesterase | |
| RU2010100971A (ru) | Аминосоединение и его фармацевтическое применение | |
| EP1405824A3 (fr) | Compositions solides génératrices d'hydrogène par combustion comprenant un borohydrure alcalin ou alcalino-terreux et sel oxydant à base de perchlorate d'ammonium, alcalin ou alcalino-terreux | |
| FR2997941B1 (fr) | Procede de preparation de sulfure de metal alcalin | |
| CO4790128A1 (es) | Composiciones sinergicas que contienen piridaben, fenoxpiro- xamato, tebufenpirad y al menos un amido compuesto, y metodo para controlar hongos fitodaninos | |
| CA2519110A1 (fr) | Derives du benzenesulfonamide, leur procede de preparation et leur utilisation dans le traitement de la douleur | |
| FR3080381B1 (fr) | Utilisation d'une composition fluorescente pour la securisation de produit | |
| MA57424B1 (fr) | Composition agrochimique de triazoles | |
| FR3071850B1 (fr) | Composition d’additifs pour carburant |